An anonymous reader quotes a report from Scientific American: This week doctors announced they had completed the first successful transplant of a partial face and an entire eye. In May at NYU Langone Health in New York City, the surgery was performed on a 46-year-old man who had suffered severe electrical burns to his face, left eye and left arm. He does not yet have vision in the transplanted eye and may never regain it there, but early evidence suggests the eye itself is healthy and may be capable of transmitting neurological signals to the brain. The feat opens up the possibility of restoring the appearance -- and maybe even sight -- of people who have been disfigured or blinded by injuries. Researchers caution there are many technical hurdles before such a procedure can effectively treat vision loss, however.

"I think it's an important proof of principle," says Jeffrey Goldberg, a professor and chair of ophthalmology at the Byers Eye Institute at Stanford University, who was not involved in the surgery but has been part of a team working toward whole-eye transplants in humans. "I think it points to the opportunity and importance that we really stand on the verge of being able to [achieve] eye transplants and vision restoration for blind patients more broadly."But he cautions that the main obstacle is achieving regeneration of the optic nerve, which carries visual signals from the retina to the brain; this step has not yet been successfully demonstrated in humans.

Scientists have been working toward whole-eye transplantation for many years. "This has been, I would say, science fiction for a long time," says Jose-Alain Sahel, a professor and chair of the department of ophthalmology at the University of Pittsburgh School of Medicine, who has been working toward such transplants with Goldberg and others. Progress in surgical techniques and nerve regeneration have made this goal seem more attainable. [...] "The fact that this surgery was successful is wonderful news," Sahel says. He cautions that surgery is only a small part of the issues that need to be addressed in order to restore eye function, however. These include making sure the immune system doesn't reject the donor eye, which is a challenge with any type of transplant. Then the corneal nerve -- which carries sensory signals from the transparent part of the eye -- must be reconnected. Yet the most complex part is regenerating the optic nerve. In order to do so, surgeons have to coax the nerve fibers to grow to the right place, which Sahel says could take months or even years. And complete optic nerve regeneration has not yet been successfully achieved in humans or other mammals.

Long-time Slashdot reader Alain Williams writes: Apple co-founder Steve Wozniak is in the hospital in Mexico, according to multiple reports.

It is not currently clear what the cause is. The 73-year-old was in Mexico City attending the World Business Forum (WBF), a business conference. [According to TMZ, Wozniak finished his speech but then told his wife he was "feeling strange." She reportedly insisted he go to the hospital.] An unnamed source from the WBF said that Mr Wozniak fainted on Wednesday at the event [minutes before his participation], according to CNN. TMZ reports that Wozniak was hospitalized after "suffering what appears to be vertigo." Mexican media outlets were reporting that it was due to a possible stroke.

An anonymous reader quotes a report from the Financial Times: Amazon Prime members will be able to access US healthcare provider One Medical's suite of benefits, for a fee, as the ecommerce company looks to expand its presence in the $4 trillion American healthcare industry. Prime members in the US who opt in will have access to unlimited, on-demand virtual healthcare via One Medical, the subscription-based group that Amazon acquired last year for $3.9 billion. They will also be able to schedule in-person appointments that they will either pay for themselves or that will be covered by insurance.

The addition to Amazon's flagship Prime membership program comes as the company looks to "stack" healthcare services together and broaden its reach in the sector, which would be "big for us if we do a good job," said Neil Lindsay, senior vice-president of Amazon Health. The subscription will cost Amazon Prime members $9 per month or $99 per year, compared with the standard One Medical subscription fee of $199 per year. That will come on top of the $139 per year, or $14.99 a month, price for a Prime subscription.

The move is Amazon's latest effort to leverage its loyal base of Prime members and become a big player in the healthcare industry. In January, following its 2018 acquisition of mail-order pharmacy PillPack for about $1 billion, Amazon launched RxPass, which allows Prime members to order an unlimited amount of some unbranded prescription medications for $5 a month. It has also rolled out a "Clinic" telehealth service that connects patients with clinicians and a broader mail-order pharmacy service.

The scientific literature is polluted with fake manuscripts churned out by paper mills -- businesses that sell bogus work and authorships to researchers who need journal publications for their CVs. But just how large is this paper-mill problem? From a report: An unpublished analysis shared with Nature suggests that over the past two decades, more than 400,000 research articles have been published that show strong textual similarities to known studies produced by paper mills. Around 70,000 of these were published last year alone. The analysis estimates that 1.5-2% of all scientific papers published in 2022 closely resemble paper-mill works. Among biology and medicine papers, the rate rises to 3%.

Without individual investigations, it is impossible to know whether all of these papers are in fact products of paper mills. But the proportion -- a few per cent -- is a reasonable conservative estimate, says Adam Day, director of scholarly data-services company Clear Skies in London, who conducted the analysis using machine-learning software he developed called the Papermill Alarm. In September, a cross-publisher initiative called the STM Integrity Hub, which aims to help publishers combat fraudulent science, licensed a version of Day's software for its set of tools to detect potentially fabricated manuscripts.

Paper-mill studies are produced in large batches at speed, and they often follow specific templates, with the occasional word or image swapped. Day set his software to analyse the titles and abstracts of more than 48 million papers published since 2000, as listed in OpenAlex, a giant open index of research papers that launched last year, and to flag manuscripts with text that very closely matched known paper-mill works. These include both retracted articles and suspected paper-mill products spotted by research-integrity sleuths such as Elisabeth Bik, in California, and David Bimler (also known by the pseudonym Smut Clyde), in New Zealand.

An anonymous reader quotes a report from Motherboard: [A] new tech startup, Prophetic, aims to bring lucid dreams to a much wider audience by developing a wearable device designed to spark the experience when desired. Prophetic is the brainchild of Eric Wollberg, its chief executive officer, and Wesley Louis Berry III, its chief technology officer. The pair co-founded the company earlier this year with the goal of combining technologies, such as ultrasound and machine learning models, "to detect when dreamers are in REM to induce and stabilize lucid dreams" with a device called the Halo according to the company's website. [...]

Prophetic does not make any medical claims about its forthcoming products -- Halo is tentatively slated for a 2025 release -- though Wollberg and Berry both expressed optimism about broader scientific research that suggests lucid dreams can reduce PTSD-related nightmares, promote mindfulness, and open new windows into the mysterious nature of consciousness. To explore those links further, Prophetic has partnered with the Donders Institute, a research center at Radboud University in the Netherlands that is focused on neuroscience and cognition, to generate the largest dataset of electroencephalogram (EEG) and functional magnetic resonance imaging (fMRI) observations of lucid dreamers, according to the company. The collaboration will also explore one of central technologies behind Prophetic's vision, known as transcranial focused ultrasound (TUS). This non-invasive technique uses low-intensity ultrasound pulses to probe the brain, and interact with neural activity, with a depth and precision that cannot be achieved with previous methods, such as transcranial electrical stimulation or transcranial magnetic stimulation.

At this point, both the possibilities and limits of Prophetic's concept remain unclear. While ultrasound devices have been widely used in medicine for decades, the process of stimulating parts of the brain with TUS is a relatively new development. Within the past few years, scientists have shown that TUS "has the potential to be used both as a scientific instrument to investigate brain function and as a therapeutic modality to modulate brain activity," according to a 2019 study, and "could be a useful tool in the treatment of clinical disorders characterized by negative mood states, like depression and anxiety disorders," according to a 2020 study. What is not known, yet, is whether TUS can induce or stabilize lucid dreams, though the Prophetic team is banking on a positive answer to this open question. Its wearable headband prototype, the Halo, was developed with the company Card79 and can currently read EEG data of users. Over the next year, Prophetic aims to use the dataset from their partnership with the Donders Institute to train machine learning models that will stimulate targeted neural activity in users with ultrasound transducers as a means of inducing lucid dreams.

An anonymous reader quotes a report from The Guardian: Marc, 63, from Bordeaux, France, was diagnosed with the degenerative disease more than 20 years ago and had developed severe mobility problems, including balance impairments and freezing of gait. After receiving the implant, which aims to restore normal signaling to the leg muscles from the spine, he has been able to walk more normally and regained his independence. "I practically could not walk any more without falling frequently, several times a day. In some situations, such as entering a lift, I'd trample on the spot, as though I was frozen there, you might say," he said. "Right now, I'm not even afraid of the stairs any more. Every Sunday I go to the lake, and I walk around 6 kilometers [3.7 miles]. It's incredible."

The implant is yet to be tested in a full clinical trial. But the Swiss team, who have a longstanding program to develop brain-machine interfaces to overcome paralysis, hope that their technology could offer an entirely new approach to treating movement deficits in those with Parkinson's disease. "It is impressive to see how by electrically stimulating the spinal cord in a targeted manner, in the same way as we have done with paraplegic patients, we can correct walking disorders caused by Parkinson's disease," said Jocelyne Bloch, neurosurgeon and professor at the CHUV Lausanne University hospital, who co-led the work.

First, the team developed a personalized anatomical map of Marc's spinal cord that identified the precise locations that were involved in signaling to the leg to move. Electrodes were then implanted at these locations, allowing stimulation to be delivered directly into the spine. The patient wears a movement sensor on each leg and when walking is initiated the implant automatically switches on and begins delivering pulses of stimulation to the spinal neurons. The aim is to correct abnormal signals that are sent from the brain, down the spine, to the legs in order to restore normal movement. "At no point is [the patient] controlled by the machine," said Prof Eduardo Martin Moraud, of Lausanne University hospital. "It's just enhancing his capacity to walk." The study, published in Nature Medicine, found that the implant improved walking and balance deficits and when Marc's walking was analyzed it more closely resembled that of healthy controls than that of other Parkinson's patients. Marc also reported significant improvements in his quality of life.

Many Americans want to abolish Daylight Saving Time, reports NBC News: Since 2018, nearly all states have passed or entertained legislation that would drop the twice-a-year time shift. And 19 states have passed laws or resolutions in support of year-round daylight saving time, according to data from the National Conference of State Legislatures. But there's a caveat: Nothing can change until Congress addresses a 1960s-era law blocking such action.
"This ritual of changing time twice a year is stupid," U.S. Senator Marco Rubio said in March, reintroducing legislation to end Daylight Saving Time. In an official statement the Senator announced that "Locking the clock has overwhelming bipartisan and popular support. This Congress, I hope that we can finally get this done."

But according to the Hill, "Both the House and Senate versions of the Sunshine Protection Act of 2023 haven't appeared to go far. The Senate bill has been read twice and referred to a committee, while the House bill has only been referred to a subcommittee."

While America waits, another medical association has come out in favor of ending Daylight Saving Time, reports NBC News: The American Academy of Sleep Medicine is a medical association whose professionals advocate for policies that improve sleep health. On Tuesday, the academy released a statement calling on the U.S. to eliminate daylight saving time completely, stating that standard time best supports health and safety, as it aligns with people's natural circadian rhythm. Undergoing the time switch itself raises the most concerns. Research shows that after the "spring forward" time change, workplace injuries, car crash deaths and heart attack risk have all increased. One 2023 study found that a week after transitioning from the time change, people reported more dissatisfaction with sleep and higher rates of insomnia.

"Software that controls your body should always respect your freedom," warns the program manager of the Free Software Foundation: In July, users of the proprietary software app LibreLink, who live in the UK and use Apple devices, found that the app they depend on to monitor their blood sugar was not working anymore after the developer Abbott pushed an update for the app... Despite what its name may suggest, there is nothing libre about the LibreLink app. It's proprietary software, which means users must depend on the company to keep it running and to distribute it. With free software, [a user] would have had the freedom to run, copy, distribute, study, change, and improve the software himself, or he could have leaned on a community of developers and users to share and fix the software, and the old version of the software would have been available to revert the update...

Two months later, with Apple's update to iOS 17, users of the FreeStyle LibreLink and Libre 2 apps had reason again to fear that the software they rely on wouldn't work after updating their iPhones. This time, users all over the world were affected. In September, Abbott warned Apple users: "As part of the upcoming iOS 17 release, Apple is introducing StandBy Mode and Assistive Access Mode ... this release may impact your experience with the FreeStyle Libre 2 app, the FreeStyle LibreLink app, or the FreeStyle LibreLinkUp app. We recommend that you disable automatic operating system updates on the smartphone using the mentioned apps." This warning was made because StandBy Mode would sometimes prohibit time-sensitive notifications such as glucose alarms, and the Assistive Access Mode would impact sensor activation and alarm setting modification in the app...

And a scenario where a company abandons service or updates to its users is not merely theoretical. This is the bitter reality faced by users of eye implants produced by Second Sight Medical Products since the company decided to abandon the technology in 2020 when facing the prospect of bankruptcy. [">According to IEEE Spectrum], Terry Byland, whose sight has been dependent on the first-generation Argus implant since 2004, says of his experience, "As long as nothing goes wrong, I'm fine. But if something does go wrong with it, well, I'm screwed. Because there's no way of getting it fixed." That's what also happened to Barbara Campbell, whose retinal implant suddenly stopped working when she was on a subway...

It's up to us advocates of free software to inform the people around us of the issues with proprietary software in medical aids. Let's encourage our friends, parents, and grandparents to ask their doctor about the software in their medical devices and to choose and insist upon free software over proprietary software.

The Food and Drug Administration is warning consumers to ditch 26 over-the-counter eye drop products found at big retailers -- including CVS, Rite Aid, and Target -- due to a risk of infection. Consumers should not buy any of the products and should immediately stop using them if they've already purchased them. From a report: The products include Target's branded Up & Up Dry Eye Relief Lubricant Eye Drops and Up & Up Extreme Relief Dry Eye, as well as Lubricant Eye Drops and Lubricant Gel Drops branded by CVS Health and Rite Aid. The warning also includes eye drop products branded as Rugby and Leader (both from Cardinal Health) and Velocity Pharma. A full list can be found here, as can links to report adverse events.

In an advisory posted Friday, the FDA reported that no infections or adverse events have been linked to the products so far. But the agency said it "found insanitary conditions in the manufacturing facility and positive bacterial test results from environmental sampling of critical drug production areas in the facility."

Are face masks effective in stopping virus transmissions? CBS News re-visited the question Sunday on its news show 60 Minutes by sending their chief medical correspondent to interview Linsey Marr, a professor who specializes in aerosol science at Virginia Tech University.

Here's a transcript from an excerpt posted on YouTube: 60 Minutes: Is there any doubt in your mind that masks prevent the person who's wearing it from getting Covid — or at least, are helpful?

Professor Marr: I would say they are very helpful in reducing the chances that the person will get Covid. Because it's reducing the amount of virus that you would inhale from the air around you.

It's not going to guarantee that it's going to protect you, because are masks are not 100% effective — we talk about N-95's being 95% efficient at filtering out particles, if they're properly fitted and everything, and so that's in an ideal world. But even so, if you — instead of breathing in 100 virsues, I'm breathing in 20, because my mask was 80% effective? That's a huge reduction, and that greatly reduces the chance that I'm going to become infected.
On the CBS News web site, they highlight this excerpt from the interview: Early in the pandemic, some guidance from health professionals suggested that wearing a mask might actually lead to infection: A person might encounter a contaminated mask and then touch their eyes, nose, or mouth. But research in the ensuing years has shown that fear to be misplaced. "There wasn't any evidence really that that happens," Marr said.

Marr said her team aerosolized the coronavirus, pulled it through a mask, and then examined how much virus survived on the mask. The study reported some viral particle remained on some cloth masks, but no virus survived on the N95s or surgical masks. Marr's team also touched artificial skin to masks and looked at how many virus particles transferred to the artificial skin. No infectious virus transferred.

"I hope the study kind of shows that it's something we don't need to worry about as much as we were told," Marr said.
CBS gave their video interview the headline "Face mask effectiveness: What we know now" — and asked professor Marr for a definitive answer: 60 Minutes: There was a lot of controversy over whether or not masks worked at all. Were you able to show that they worked scientifically?

Professor Marr: We were able to show that they block particles that are the same size as those that carry the virus... What happens is the virus is being carried in the air, and it's not just going straight through those holes. It has to weave around all these layers of fibers in there. As the air is going around the curves, the virus may crash into one of those fibers, and so then it's trapped, or maybe it comes up close to the fiber and brushes against it. And the really small particles, like the virus by itself if it were by itself, would be small enough that it undergoes these random motions, because it's getting bounced around by the gas molecules, and it ends up crashing into the fibers of the mask too.

So there was accumulating evidence — and there had been kind of a handful of papers before that, too, showing the same thing. That masks — even cloth masks — do something.

An anonymous reader quotes a report from KOMO News: A groundbreaking medical procedure for those with kidney stones will soon be offered at the University of Washington after more than two decades of research. It will also give astronauts the go ahead they need from NASA to travel to Mars. It's a groundbreaking procedure to get rid of painful stones while you're awake, no anesthesia needed. "This has the potential to be game changing," said Dr. Kennedy Hall with UW Medicine. Still being run through clinical trials at UW Medicine, the procedure called burst wave lithotripsy uses an ultrasound wand and soundwaves to break apart the kidney stone. Ultrasonic propulsion is then used to move the stone fragments out, potentially giving patients relief in 10 minutes or less.

This technology is also making it possible for astronauts to travel to Mars, since astronauts are at a greater risk for developing kidney stones during space travel. It's so important to NASA, the space agency has been funding the research for the last 10 years. "They could potentially use this technology while there, to help break a stone or push it to where they could help stay on their mission and not have to come back to land," said Harper. The research has been published in the Journal of Urology.

A new study published in the British Journal of Sports Medicine finds that about 22 minutes a day of moderate to vigorous activity may combat the negative effects of prolonged sitting. Furthermore, they researchers found that as a person's activity level increases, the risk of dying prematurely from any cause goes down. NBC News reports: In the study, researchers looked at information from nearly 12,000 people ages 50 and older in four datasets from Norway, Sweden and the United States. In those datasets, the participants wore movement detection devices on their hips for 10 hours a day for at least four days. All of the individuals included in the new study were tracked for at least two years. In the new analysis, the researchers accounted for factors, including medical conditions, that could've affected risk of early death. About half of the participants spent 10 1/2 hours or more sedentary each day.

When the researchers linked the participants' information with death registries in the different countries, they found that over an average of five years, 805 people, or 17%, had died. Of those who died, 357, or 6%, had spent less than 10 1/2 hours a day seated, while 448 averaged 10 1/2 hours or more sedentary. Sitting for more than 12 hours a day, the researchers found, was associated with a 38% increased risk of death as compared to eight hours, but only among those who managed to get less than 22 minutes of moderate to vigorous activity a day.

The risk of death went down with increasing amounts of physical activity. An extra 10 minutes a day translated into a 15% lower risk of death among those spending fewer than 10 1/2 hours seated and a 35% lower risk among those who spent more than 10 1/2 hours sedentary each day. Lower intensity activity only made a difference among participants who spent 12 or more hours sitting every day. The study's lead author, Edvard Sagelv, a researcher at The Arctic University of Norway, broke the findings down into manageable terms. "Think of it: only 20 minutes of this a day is enough, meaning, a small stroll of 10 minutes twice a day -- like jumping off the bus one stop before your actual destination to work and then when taking the bus back home, jumping off one stop before."

An anonymous reader quotes a report from MIT Technology Review: Egbert Edelbroek was acting as a sperm donor when he first wondered whether it's possible to have babies in space. Curious about the various ways that donated sperm can be used, Edelbroek, a Dutch entrepreneur, began to speculate on whether in vitro fertilization technology was possible beyond Earth -- or could even be improved by the conditions found there. Could the weightlessness of space be better than a flat laboratory petri dish? Now Edelbroek is CEO of SpaceBorn United, a biotech startup seeking to pioneer the study of human reproduction away from Earth. Next year, he plans to send a mini lab on a rocket into low Earth orbit, where in vitro fertilization, or IVF, will take place. If it succeeds, Edelbroek hopes his work could pave the way for future space settlements.

"Humanity needs a backup plan," he says. "If you want to be a sustainable species, you want to be a multiplanetary species." Beyond future space colonies, there is also a more pressing need to understand the effects of space on the human reproductive system. No one has ever become pregnant in space -- yet. But with the rise of space tourism, it's likely that it will eventually happen one day. Edelbroek thinks we should be prepared. Despite the burgeoning interest in deep space exploration and settlement, prompted in part by billionaires such as Elon Musk and Jeff Bezos, we still know very little about what happens to our reproductive biology when we're in orbit. A report released in September by the US National Academies of Science, Engineering, and Medicine points out that almost no research has been done on human reproduction in space, adding that our understanding of how space affects reproduction is "vital to long-term space exploration, but largely unexplored to date."

Some studies on animals have suggested that the various stages of reproduction -- from mating and fertilization to embryo development, implantation, pregnancy, and birth -- can function normally in space. For example, in the very first such experiment, eight Japanese medaka fish developed from egg to hatchling aboard the space shuttle Columbia in 1994. All eight survived the return to Earth and seemed to behave normally.Yet other studies have found evidence that points to potential problems. Pregnant rats that spent much of their third trimester -- a total of five days -- on a Soviet satellite in 1983 experienced complications during labor and delivery. Like all astronauts returning to Earth, the rats were exhausted and weak. Their deliveries lasted longer than usual, likely because of atrophied uterine muscles. All the pups in one of the litters died during delivery, the result of an obstruction thought to be due in part to the mother's weakened state.

To Edelbroek, these inconclusive results point to a need to systematically isolate each step in the reproductive process in order to better understand how it is affected by conditions like lower gravity and higher radiation exposure. The mini lab his company developed is designed to do exactly that. It is about the size of a shoebox and uses microfluidics to connect a chamber containing sperm to a chamber containing an egg. It can also rotate at different speeds to replicate the gravitational environment of Earth, the moon, or Mars. It is small enough to fit inside a capsule that can be housed on top of a rocket and launched into space.After the egg has been fertilized in the device, it splits into two cells, each of which divides again to form four cells and so on. After five to six days, the embryo reaches a stage known as a blastocyst, which looks like a hollow ball. At this point, the embryos in the mini lab will be cryogenically frozen for their return to Earth.

One month after an experimental procedure to transplant the heart of a genetically modified pig into a patient with end-stage heart disease, doctors say the heart is functioning on its own and shows no signs of rejection. From a reoport: In September, 58-year-old Lawrence Faucette underwent the surgery, only the second ever performed in a human. Faucette's heart disease and pre-existing conditions made him ineligible for a traditional human heart transplant. "The physicians taking care of him believe his heart function is excellent," said Dr. Bartley Griffith, director of the Cardiac and Lung Transplant Program at the University of Maryland School of Medicine who performed the surgery. "We've had no evidence of infections and no evidence of rejection right now."

Dr. Muhammad Mohiuddin, director of UMMC's Cardiac Xenotransplantation Program, said in an update shared on Friday, "we are withdrawing all the drugs that were initially supporting his heart. So now his heart is doing everything on its own." Mohiuddin said the focus now is making sure that Faucette has the strength to perform routine functions. "We are working very hard with our physical therapy team who are spending a lot of time helping him regain the strength that he's lost during last one month of hospital stay," Mohiuddin said.

The White House on Monday announced it is designating 31 technology hubs in an effort to improve American competitiveness in the technology sector. The hubs will be able to compete for $40 million to $75 million each in grants, the White House said. From a report: A tech hub designation is "a strong endorsement of a region's plan to supercharge a critical technology ecosystem and become a global leader over the next decade," the U.S. Economic Development Administration said on its website. The move was authorized under the CHIPS and Science Act, the White House said, which President Joe Biden frequently touts as a highlight of his economic agenda. The act, which the president signed in August 2022, aimed to improve semiconductor manufacturing and supply chains in the U.S. It also authorized $10 billion to invest in technology hubs nationwide, according to the administration.

"These Tech Hubs will catalyze investment in technologies critical to economic growth, national security, and job creation, and will help communities across the country become centers of innovation critical to American competitiveness," the White House said in a news release. The hubs focus on a wide range of technological areas, including quantum computing, artificial intelligence, clean energy, medicine and biotechnology. The location of the hubs spans 32 states and Puerto Rico and include areas with a tribal government, coal communities and states with smaller populations, according to the U.S. Economic Development Administration.

Pfizer this week revealed that it raised the list price of a course of Paxlovid -- its lifesaving antiviral drug used to reduce the risk of severe COVID-19 in those most vulnerable -- to nearly $1,400, more than double the roughly $530 the US government has paid for the treatment in the emergency phase of the pandemic. From a report: Pfizer CEO Albert Bourla had noted in an investor call at the beginning of the week that the company would increase the price of Paxlovid as it moves from government distribution to the commercial market at the end of this year. But, he did not announce the new list price then. Instead, the company revealed the more than twofold increase in a letter to pharmacies and clinics dated Wednesday. The Wall Street Journal was the first to report the list price of $1,390 after viewing the letter.

A Pfizer spokesperson told the Journal that "pricing for Paxlovid is based on the value it provides to patients, providers, and health care systems due to its important role in helping reduce COVID-19-related hospitalizations and deaths." A cost-effectiveness analysis last year determined the value of Paxlovid at between $563 and $906 per treatment course, according to nonprofit drug-pricing watchdog The Institute for Clinical and Economic Review.

An anonymous reader quotes a report from VICE News: Canada will legalize medically assisted dying for people who are addicted to drugs next spring, in a move some drug users and activists are calling "eugenics." The country's medical assistance in dying (MAID) law, which first came into effect in 2016, will be expanded next March to give access to people whose sole medical condition is mental illness, which can include substance use disorders. Before the changes take place, however, a special parliamentary committee on MAID will regroup to scrutinize the rollout of the new regulations, according to the Toronto Star.

Currently, people are eligible for MAID if they have a "grievous and irremediable medical condition", such as a serious illness or disability, that has put them in an advanced state of irreversible decline and caused enduring physical or psychological suffering -- excluding mental illness. Anyone who receives MAID must also go through two assessments from independent health care providers, among meeting other criteria. [...] As Canada prepares to legalize MAID for people with mental disorders, each province will have to develop its own protocol for how to assess people. Dr. Simon Colgan, lead physician for the Community Allied Mobile Palliative Partnership which provides palliative care to homeless people, said MAID requests "must be understood within the context of a person's lived experience and this takes time and relationship." He said any MAID protocols for people with substance use disorders should be made with the input of people with lived experiences. "I don't think it's fair, and the government doesn't think it's fair, to exclude people from eligibility because their medical disorder or their suffering is related to a mental illness," said Dr. David Martell, physician lead for Addictions Medicine at Nova Scotia Health. "As a subset of that, it's not fair to exclude people from eligibility purely because their mental disorder might either partly or in full be a substance use disorder. It has to do with treating people equally."

On the flip side, some drug users and harm reduction advocates say they're upset drug users are being given access to MAID, as they feel other public health measures are lacking. "I just think that MAID when it has entered the area around mental health and substance use is really rooted in eugenics. And there are people who are really struggling around substance use and people do not actually get the kind of support and help they need," said Zoe Dodd, a Toronto-based harm reduction advocate.

Karen Ward, a drug user activist in Vancouver, said she considers the expansion of MAID to include people with substance use disorders a "statement in federal law that some people aren't really human." "The government has made death accessible while a better life remains impossible," she said. "Homes for all, guaranteed dignified incomes, access to healthcare, education and employment: these aren't radical demands."

Amazon has started delivering prescription medications by drone in a Texas city, broadening its still-experimental effort to deliver goods by air. From a report: The online retailer recently began listing drone delivery as an option for Amazon Pharmacy customers who are participating in a test program in College Station, one of two US cities where Amazon is delivering products using its unmanned, riding-lawnmower-sized vehicles. The company made the effort public on Wednesday ahead of a logistics press event held at a warehouse near Amazon's Seattle headquarters.

Quick delivery of medical supplies has emerged as one of the leading candidates for a viable delivery-by-drone business. Alphabet's Wing, United Parcel Service and drone startup Zipline have all set out to deliver medical goods, sometimes in trial programs centered around hospital campuses or planned communities. In most places, drone use remains limited to narrowly prescribed tests as regulators hash out regulations to limit risk to other aircraft and people on the ground.

Katalin Kariko and Drew Weissman, who together identified a chemical tweak to messenger RNA, were awarded the Nobel Prize in Physiology or Medicine on Monday. Their work enabled potent Covid vaccines to be made in less than a year, averting tens of millions of deaths and helping the world recover from the worst pandemic in a century. From a report: The approach to mRNA the two researchers developed has been used in Covid shots that have since been administered billions of times globally and has transformed vaccine technology, laying the foundation for inoculations that may one day protect against a number of deadly diseases like cancer. The slow and methodical research that made the Covid shots possible has now run up against a powerful anti-vaccine movement, especially in the United States. Skeptics have seized in part on the vaccines' rapid development -- among the most impressive feats of modern medical science -- to undermine the public's trust in them.

But the breakthroughs behind the shots unfolded little by little over decades, including at the University of Pennsylvania, where Dr. Weissman runs a lab. [...] The mRNA work was especially frustrating, she said, because it was met with indifference and a lack of funds. She said she was motivated by more than not being called a quitter; as the work progressed, she saw small signs that her project could lead to better vaccines. "You don't persevere and repeat and repeat just to say, 'I am not giving up,'" she said.

An anonymous reader quotes a report from Motherboard: Scientists have witnessed brain patterns in dying patients that may correlate to commonly reported "near-death" experiences (NDEs) such as lucid visions, out-of-body sensations, a review of one's own life, and other "dimensions of reality," reports a new study. The results offer the first comprehensive evidence that patient recollections and brain waves point to universal elements of NDEs. During an expansive multi-year study led by Sam Parnia, an intensive care doctor and an associate professor in the department of medicine at NYU Langone Health, researchers observed 567 patients in 25 hospitals around the world as they underwent cardiopulmonary resuscitation (CPR) after suffering cardiac arrest, most of which were fatal.

Electroencephalogram (EEG) brain signals captured from dozens of the patients revealed that episodes of heightened consciousness occurred up to an hour after cardiac arrest. Though most of the patients in the study were sadly not resuscitated by CPR, 53 patients were brought back to life. Of the survivors, 11 patients reported a sense of awareness during CPR and six reported a near-death experience. Parnia and his colleagues suggest that the transition from life to death can trigger a state of disinhibition in the brain that "appears to facilitate lucid understanding of new dimensions of reality -- including people's deeper consciousness -- all memories, thoughts, intentions and actions towards others from a moral and ethical perspective," a finding with profound implications for CPR research, end-of-life care, and consciousness, among other fields, according to a new study published in Resuscitation. [...]

"One of the things that was unique about this project is that this was the first time ever where scientists had put together a method to examine for signs of lucidity and consciousness in people as they're being revived by looking for brain markers, or brain signatures of consciousness, using an EEG device as well as a brain oxygen monitor," Parnia explained. "Most doctors are taught and believe that the brain dies after about five or 10 minutes of oxygen deprivation," Parnia said. "One of the key points that comes out of this study is that that is actually not true. Although the brain flatlines after the heart stops, and that happens within seconds, it doesn't mean that it's permanently damaged and [has] died. It's just hibernating. What we were able to show is that actually, the brain can respond and restore function again, even after an hour later, which opens up a whole window of opportunity for doctors to start new treatments." Indeed, the study reports that "near-normal/physiological EEG activity (delta, theta, alpha, beta rhythms) consistent with consciousness and a possible resumption of a network-level of cognitive and neuronal activity emerged up to 35-60 minutes into CPR. This is the first report of biomarkers of consciousness during CA/CPR."